NCT01652859已完成1 期
An Open-label, Randomized, Balanced, Crossover Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects
Taiwan Liposome Company0 个研究点目标入组 36 人开始时间: 2012年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 主要终点
- The bioequivalence of two different liposomal amphotericin B injections
研究概览
简要总结
The 2 × 2 crossover designed study is to evaluate the bioequivalence of two different liposomal amphotericin B injections after single IV infusion at the same dose in normal healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must be adults (> 20 years old) in good health on the basis of medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.
- •Vital signs (after 3 minutes resting in a upright position) which are within the following ranges: Ear body temperature between 35.0-37.5 °C. Systolic blood pressure, 90-140 mm Hg. Diastolic blood pressure, 50-90 mm Hg. Pulse rate, 50-90 bpm
- •Fasting blood glucose < 100 mg/dL.
- •Body weight must be above 50 kg for men and 45 kg for women and within 20% of ideal body weight.
- •Negative urine drug screen at clinic check-in before each dosing
- •Able to sign informed consent prior to study.
- •Able to communicate well with the investigator and comply with the requirements of the study.
- •Pregnancy tests (female only): negative reaction
排除标准
- •Use of any prescription or over the counter medication within 14 days prior to investigational products administration; with the exception of acetaminophen (not more than 2 g/day) or vitamins.
- •A plan to take concomitant medications while enrolled in the study, with the exception of acetaminophen (not more than 2 g/day) or vitamins.
- •Presence of any acute or chronic medical condition within 2 weeks prior to investigational products administration, including but not limited to: hepatic, gastrointestinal, renal, hematologic (including coagulation), pulmonary, neurologic, respiratory, endocrine, or cardiovascular system abnormalities; psychiatrical disease including major psychiatric disorders (e.g., schizophrenia, bipolar disorder); acute infection; or other conditions that would interfere with the absorption, distribution, metabolism, or excretion of drugs. Evidence of impaired renal function as indicated by clinically significant abnormal creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria) as judged by the investigator. Evidence of liver disease, hepatitis B, hepatitis C or liver injury as indicated by an clinically significant abnormal liver function profile such as GOT, GPT, g-GT, alkaline phosphatase, serum bilirubin, HBs Ag, or HCV Ab as judged by the investigator.
- •Hemoglobin less than 12 g/dL
- •Participation in any clinical investigation within 2 months or 5 half-lives, whichever is longer, prior to investigational products administration.
- •Donation or loss of more than 500 mL blood within 3 months prior to investigational products administration.
- •Subject is known for HIV infected.
- •Known allergy or hypersensitivity to amphotericin B or its analogs.
- •History of drug or alcohol abuse within 12 months prior to investigational products administration ; current consumption of alcohol in excess of 28 units/week (one unit is 6 oz of beer, ½ oz of hard liquor, or 2 oz of wine)
- •Subjects who, in the opinion of the investigator, should not participate in the study or may not be capable of following the study schedule for any reason.
- •Consumption of more than 36 to 40 oz (1.1-1.2 L) of caffeine-containing beverages per day
- •Consumption of any products containing grapefruit in the 3 days before clinic check-in.
研究组 & 干预措施
AmBisome
Active Comparator
RLD
干预措施: AmBisome (Drug)
Liposomal Amphotericin B
Experimental
Generic drug
干预措施: Liposomal Amphotericin B (Drug)
结局指标
主要结局
The bioequivalence of two different liposomal amphotericin B injections
时间窗: 14 days
90% CI of Cmax and AUCinf of Liposomal and non-liposomal Amphotericin B between Ambil and AmBisome within 80.00%\~125.00%.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different FormulationsHealthyNCT02070796UCB Pharma SA50
已完成
2 期
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal InfectionsAcute Myelogenous LeukemiaMyelodysplastic SyndromeNCT00418951M.D. Anderson Cancer Center120
已完成
1 期
A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy SubjectsHealthyNCT02821338Food and Drug Administration (FDA)30
已完成
1 期
Rosuvastatin Calcium Bioequivalence Study - FastHypercholesterolaemiaNCT01711749GlaxoSmithKline60
已完成
1 期
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy SubjectsHealthyNCT02019485Johnson & Johnson Pharmaceutical Research & Development, L.L.C.64